Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Glycogen storage disease due to aldolase A deficiency is an extremely rare glycogen storage disease characterized by hemolytic anemia with or without myopathy or intellectual deficit. Myopathy can be severe enough to result in fatal rhabdomyolysis in some patients. A family with episodic rhabdomyolysis (triggered by fever) without hemolytic anemia has recently been reported.
Features include always present findings: Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Muscle fiber splitting, Low muscle tone (hypotonia), and Enlarged liver (hepatomegaly) and others; and very common findings: Fever and Reduced circulating aldolase concentration. 47 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 12 | Muscle fiber splitting, Myopathy, Low muscle tone (hypotonia) |
Blood and immune system | 7 | Low red blood cell count (anemia), Enlarged spleen (splenomegaly), Hemoglobinuria |
Lab test results | 6 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Decreased erythrocyte fructose-1,6-bisphosphate aldolase activity, Elevated circulating alanine aminotransferase concentration |
Digestive system | 4 | Enlarged liver (hepatomegaly), Jaundice, Enlarged spleen (splenomegaly) |
Brain and nerves | 3 | Intellectual disability, Delayed speech and language development, Specific learning disability |
Growth and development | 2 | Short stature, Growth delay |
Eyes | 1 | Ptosis |
Hormones | 1 | Delayed puberty |
Metabolism | 1 | Fever |
Bones and joints | 1 | Skeletal myopathy |
Kidneys and urinary system | 1 | Acute kidney injury |
Heart and blood vessels | 1 | Arrhythmia |
Age of onset: infancy, childhood.
ALDOA encodes aldolase, fructose-bisphosphate A (364 aa). Catalyzes the reversible conversion of beta-D-fructose 1,6-bisphosphate (FBP) into two triose phosphate and plays a key role in glycolysis and gluconeogenesis. Highest expression in Muscle Skeletal (3,137 TPM) and Cells EBV-transformed lymphocytes (1,008 TPM).
Glycogen storage disease due to aldolase A deficiency is associated with mutations in the ALDOA gene on chromosome 16.
ALDOA is classified as a druggable target (Druggable Genome and Enzyme categories) with score 3.7.
Genetic testing for ALDOA is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for glycogen storage disease due to aldolase A deficiency has been reported in the published literature.
Phenotype severity distribution: 16 always present features, 2 very common features, 8 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for glycogen storage disease due to aldolase A deficiency.
53 publications have been identified in PubMed for glycogen storage disease due to aldolase A deficiency. Research spans Clinical Trial Publication (25%), Case Report / Case Series (21%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 13 | 25% |
Patient case studies | 11 | 21% |
Laboratory research | 10 | 19% |
Disease patterns and progression | 10 | 19% |
Research summaries | 4 | 8% |
Testing and diagnosis research | 3 | 6% |
New treatment approaches | 2 | 4% |
Costa MP (2026). [PMID: 41797620](https://pubmed.ncbi.nlm.nih.gov/41797620/). *Am J Med Genet A*. [Epidemiology / Natural History]
Mathiesen AS (2026). [PMID: 42350025](https://pubmed.ncbi.nlm.nih.gov/42350025/). *BMJ Open*. [Clinical Trial Publication]
Mino M (2026). [PMID: 41428406](https://pubmed.ncbi.nlm.nih.gov/41428406/). *Hepatol Res*. [Case Report / Case Series]
Liao KA (2026). [PMID: 42518514](https://pubmed.ncbi.nlm.nih.gov/42518514/). *Mol Ther Adv*. [Basic Science / Preclinical]
Halligan RK (2026). [PMID: 42493860](https://pubmed.ncbi.nlm.nih.gov/42493860/). *J Inherit Metab Dis*. [Epidemiology / Natural History]
Wen Y (2026). [PMID: 42298849](https://pubmed.ncbi.nlm.nih.gov/42298849/). *Zhonghua Er Ke Za Zhi*. [Epidemiology / Natural History]
Martins JCC (2026). [PMID: 41662339](https://pubmed.ncbi.nlm.nih.gov/41662339/). *PLoS One*. [Clinical Trial Publication]
Mueller MM (2026). [PMID: 41958685](https://pubmed.ncbi.nlm.nih.gov/41958685/). *Orthop J Sports Med*. [Epidemiology / Natural History]
Ono D (2026). [PMID: 41708563](https://pubmed.ncbi.nlm.nih.gov/41708563/). *Acta Neuropathol*. [Basic Science / Preclinical]
Choi SJ (2026). [PMID: 41407198](https://pubmed.ncbi.nlm.nih.gov/41407198/). *Am J Pathol*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:34 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center